# ABMTX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abmtx

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $50M
- Latest round: Series B (Jan 4, 2022)
- Investors on record: 13

## About

Based in Shanghai, China and established in 2016, ABMTX is medicine development company that focuses on small molecule tumor targeting drugs. The company has completed 4 rounds of funding as of 2022.

The company's main business is research and development of small molecule drugs that can break through the blood-brain barrier. The company self-developed product such as BRAF inhibitor ABM-1310 for the treatment of various malignant tumors and brain metastases.

The company plan to use the series B funding for promote the Sino-U.S. clinical research of the BRAF inhibitor ABM-1310 and the development of multiple existing preclinical projects and improve the company's research and development platform for small molecule innovative drugs into the brain.

## Funding rounds

- Series B, Jan 4, 2022, $30M — Delta Capital, HighLight Capital, Hermed Capital, Baidu Ventures, Sincere Capital, Photon Fund
- Series A, Aug 7, 2020, $20M — Kaitai Capital, Panlin Capital, Shanghai Jianyi Private Equity Fund Management, China Growth Capital, Ming Bioventures
- Series A, Jan 1, 2019 — Kaitai Capital, Wisdomont Capital, Viva Ventures Biotech

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Series A
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- Delta Capital (https://capitalatlas.ai/funds/delta-capital) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series B
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series B
- Sincere Capital (https://capitalatlas.ai/funds/sincere-capital) — Series B
- Photon Fund (https://capitalatlas.ai/funds/photon-fund) — Series B